Effects of Transcranial Magnetic Stimulation (TMS) and Cognitive Training for Alzheimer Patients
NCT ID: NCT00909285
Last Updated: 2010-07-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2009-07-31
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In the present study the investigators would like to examine if combined treatment with TMS and cognitive training (CoTra) for several weeks can produce a sustained improvement in cognitive and behavioral symptomatology of Alzheimer's disease (AD) patients. A number of in vivo neuroimaging techniques, which can be used to reliably and noninvasively assess aspects of neuroanatomy, chemistry, physiology, and pathology, hold promise.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TMS Stimulation and Cognitive Training in Alzheimer Patients
NCT01168245
Enhancing Neuroplasticity and Frontal Lobe Function in Patients With Mild Alzheimer's Disease
NCT01847586
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
NCT01825330
Effect of NeuroAD on Alzheimer Patients
NCT01825317
Cognitive Training and Brain Stimulation in Prodromal Alzheimer's Disease
NCT04265378
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment Group (#1)
TMS stimulation
TMS stimulation and cognitive training
Cognitive training
TMS stimulation and cognitive training
Control group (#2)
Sham comparator
Sham comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TMS stimulation
TMS stimulation and cognitive training
Sham comparator
Sham comparator
Cognitive training
TMS stimulation and cognitive training
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients diagnosed with early or moderate stage of Alzheimer's disease, according to the DSM-IV criteria.
* MMSE score 15 to 26
* Global Dementia rating 1 or 2
* Physically acceptable for the study as confirmed by medical history and exam, clinical laboratory results and EKG
* Spouse, family member or professional caregiver agree and capable of taking care and responsibility for the participation of the patient in the study (transportation for the patient to and from the investigator's clinic, answering questions regarding the patient's condition and assuming responsibility for medication)
* Written informed consent by patient or legally responsible caregiver.
* Able to undergo MRI scanning sessions (e.g., prior to the onset of the study, upon the attainment of the primary end-point and at the end of the study).
* Commitment to participation in six-to eighteen weeks of the trial regimen consisting of approximately1 hour TMS stimulation and cognitive training daily treatment of five days a week - six to eighteen weeks (and up to two treatments a day in case the Third TMS stimulation and cognitive training Treatment protocol if necessary).
Exclusion Criteria
* Mental retardation;
* Unstable medical condition;
* Use of benzodiazepines or other hypnotics during the study and preceding two weeks;
* Pharmacological immunosuppression;
* Participation in a clinical trial with any investigational agent within two weeks prior to study enrollment;
* Alcoholism;
* History of Epileptic Seizures or Epilepsy;
* Contraindication for performing MRI scanning;
* Clinically significant abnormal laboratory findings which have not been approved by the Project Director;
55 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assaf-Harofeh Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Assaf Harofeh Medical center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shai Efrati, MD
Role: PRINCIPAL_INVESTIGATOR
Assaf-Harofeh MC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assaf-Harofeh MC
Beer-Yaakov, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NRX -NC-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.